Orgovyx FDA Approval History
FDA Approved: Yes (First approved December 18, 2020)
Brand name: Orgovyx
Generic name: relugolix
Dosage form: Tablets
Company: Myovant Sciences
Treatment for: Prostate Cancer
Orgovyx (relugolix) is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.
Development Timeline for Orgovyx
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.